Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
451,069

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $76.35 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Zacks Equity Research

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Zacks Equity Research

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

by Zacks Equity Research

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Zacks Equity Research

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

by Zacks Equity Research

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.

Zacks Equity Research

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

by Zacks Equity Research

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Zacks Equity Research

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Zacks Equity Research

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Zacks Equity Research

Bruker (BRKR) Expands Materials Science Research via New Deal

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

Zacks Equity Research

HAE or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. SYK: Which Stock Is the Better Value Option?

Zacks Equity Research

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

by Zacks Equity Research

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Zacks Equity Research

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

by Zacks Equity Research

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Zacks Equity Research

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

by Zacks Equity Research

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

by Moumi Mondal

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Zacks Equity Research

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Zacks Equity Research

Here's Why You Should Retain Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.